Kyverna Therapeutics (KYTX) News Today $3.70 +0.01 (+0.27%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.78 +0.07 (+2.03%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Kyverna Therapeutics’ KYV-101: Promising Data and Strategic Pathway Drive Buy Rating1 hour ago | tipranks.comKyverna Therapeutics Unveils KYV-101 Phase 3 Trial Design for Myasthenia Gravis and Highlights Potential Breakthrough in Stiff Person Syndrome TreatmentAugust 28 at 8:31 AM | quiverquant.comQKyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL EventAugust 28 at 8:00 AM | globenewswire.comKyverna Therapeutics to Present at Upcoming Investor Conferences in SeptemberAugust 25, 2025 | globenewswire.comAnalysts Set Expectations for KYTX Q3 EarningsAugust 24, 2025 | marketbeat.comBrokers Set Expectations for KYTX Q3 EarningsAugust 23, 2025 | americanbankingnews.comKyverna Therapeutics (NASDAQ:KYTX) Now Covered by William BlairAugust 22, 2025 | marketbeat.comHere's Why Kyverna Therapeutics (NASDAQ:KYTX) Must Use Its Cash WiselyAugust 21, 2025 | finance.yahoo.comWilliam Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform RecommendationAugust 21, 2025 | msn.comKyverna Therapeutics initiated with an Outperform at William BlairAugust 20, 2025 | msn.comKyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026August 20, 2025 | benzinga.comKyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101August 20, 2025 | tipranks.comResearch Analysts Set Expectations for KYTX FY2025 EarningsAugust 17, 2025 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for KYTXAugust 17, 2025 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPSAugust 14, 2025 | marketbeat.comKyverna Therapeutics, Inc.: Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | finanznachrichten.deKyverna Therapeutics reports Q2 EPS (97c), consensus ($1.04)August 12, 2025 | msn.comKyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.comKyverna Therapeutics (KYTX) Expected to Announce Earnings on MondayAugust 5, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Buy" from BrokeragesAugust 4, 2025 | marketbeat.comKyverna Appoints New CFO to Guide Next Growth PhaseJuly 29, 2025 | msn.comKyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T FranchiseJuly 29, 2025 | prnewswire.comPeapod Lane Capital LLC Invests $765,000 in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)July 10, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from AnalystsJuly 10, 2025 | marketbeat.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 2, 2025 | globenewswire.comKyverna Therapeutics Names Marc Grasso Chief Financial OfficerJune 30, 2025 | marketwatch.comKyverna Therapeutics Announces Appointment of New Chief Financial OfficerJune 30, 2025 | finance.yahoo.com3 Promising Penny Stocks With Market Caps Over $100MJune 10, 2025 | finance.yahoo.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 20.6% in MayJune 4, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLCJune 1, 2025 | marketbeat.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comKyverna Therapeutics (NASDAQ:KYTX) Stock Rating Upgraded by HC WainwrightMay 28, 2025 | marketbeat.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for KYTX EarningsMay 23, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comQ1 Earnings Forecast for KYTX Issued By HC WainwrightMay 22, 2025 | marketbeat.comSphera Funds Management LTD. Decreases Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 18, 2025 | marketbeat.comWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 15, 2025 | finance.yahoo.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 15, 2025 | globenewswire.comKyverna Therapeutics Reports Q1 2025 Progress and OutlookMay 14, 2025 | tipranks.comIntegral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)May 14, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comKyverna Therapeutics (KYTX) Expected to Announce Earnings on TuesdayMay 8, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from AnalystsApril 28, 2025 | marketbeat.comGilead Sciences Inc. Acquires New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)April 20, 2025 | marketbeat.comJPMorgan Chase & Co. Trims Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)April 17, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Holdings Trimmed by Franklin Resources Inc.April 15, 2025 | marketbeat.comEquities Analysts Offer Predictions for KYTX Q1 EarningsApril 8, 2025 | marketbeat.comHC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00April 5, 2025 | marketbeat.com Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYTX Media Mentions By Week KYTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼0.901.03▲Average Medical News Sentiment KYTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼126▲KYTX Articles Average Week Get the Latest News and Ratings for KYTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Kyverna Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies KURA News SIGA News BCAX News VIR News RLAY News KROS News SNDL News MGTX News TYRA News MRVI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access